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Novel Antimicrobials to Combat Gram Positive Bacteria*
multiple bacterial targets with low 
drug concentrations (2-8 ug/ml).  
Additionally, we tested six compounds 
in acute in vitro toxicity screening in 
a rat hepatoma (H4IIE) cell line at 
24 hour exposure.  All compounds 
demonstrated minimal toxicity to the cell 
line.  These toxicity results demonstrate 
that potential negative side-effects 
to patients appear to be minimal.  
Further testing of  our antibiotics 
revealed significant binding to human 
serum protein. This is potentially 
problematic in clinical use as there is 
less available compound in the blood.  
There are conflicting opinions as to 
the significance of  binding to serum 
protein.  For example, nine of  the top 
10 best-selling small molecule, single 
agent prescription drugs of  2006 had 
90% or greater binding to serum protein 
and seven of  the top ten had 95% 
or greater [Rydzewski, R.M., 2008].  
A potential problem exists and we 
continue to work towards lowering this 
binding to increase potential available 
drug concentrations in the blood.
*This scholar and faculty mentor 
have requested that only an 
abstract be published.
A novel class of  antibacterial substances 
has been discovered in a collaborative 
project between the Chemistry and 
Biology Departments at Grand Valley 
State University (GVSU).  These 
compounds do not rely on currently 
accepted antibiotic chemical structure but 
seemingly have a mechanism of  action 
different from understood mechanistic 
pathways for treatment of  infections and 
are readily synthesized, avoiding complex, 
stereoselective, multi-step synthesis.   
This new class of  antibiotics is composed 
of  chemical derivatives of  the telomerase 
inhibitor BIBR1532 [US Patent 
6362210].  Our compounds demonstrated 
significant antimicrobial activity against a 
group of  Gram-Positive microorganisms.  
The antibiotic’s minimum inhibitory 
concentrations (MICs) against these 
bacteria are equivalent to existing 
antibiotics (2-78 ug/ml). In subsequent 
in-vitro tests these compounds showed 
activity against methicillin-resistant 
Staphylococcus aureus (MRSA), vancomycin 
resistant enterococci (VRE), Bacillus 
anthracis (anthrax), and Clostridium difficile 
(Cdiff).  The antibacterial activity against 
MRSA, VRE, and Cdiff strains of  
bacteria is promising as it demonstrates 
the ability of  BIBR 1532 to inhibit 
microbial growth in organisms with 
resistance to common antibiotics.  
In 2008, GVSU patented this antibiotic 
family.  Since then, we determined 
that the frequency of  bacterial 
resistance to this class of  antibiotics is 
extremely low.  Over 70 compounds 
were tested for antibacterial activity.  
Sixty demonstrated antibacterial 
activity and of  these 18 were more 
thoroughly tested against 25 bacterial 
and fungal strains.  We discovered 
that a number of  compounds had low 
minimum inhibitory concentrations 
(MICs) against Staphylococcus aureus 
(including MRSA strains), Bacillus 
anthracis (anthrax), Clostridium difficile, 
and  Streptococcus pneumonia.  These results 
were encouraging as they demonstrate 
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